FIBROGEN INC
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
KYNB$3.73+1.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share amounts)
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Revenue: | |||
| License revenue (includes $0, $22,590 and $108,434 from a related party) | $9,649 | $22,590 | $116,434 |
| Development and other revenue (includes $6,662, $9,908 and $21,928 from a related party) | 18,401 | 24,189 | 70,275 |
| Product revenue, net (includes $89,055, $71,167 and $35,568 from a related party) | 100,949 | 82,869 | 47,638 |
| Drug product revenue, net (includes $18,753, $11,086 and $3,186 from a related party) | 18,753 | 11,086 | 962 |
| Total revenue | 147,752 | 140,734 | 235,309 |
| Operating costs and expenses: | |||
| Cost of goods sold | 18,848 | 20,280 | 12,871 |
| Research and development | 282,861 | 296,791 | 387,043 |
| Selling, general and administrative | 115,252 | 124,688 | 123,925 |
| Restructuring charge | 12,606 | — | — |
| Total operating costs and expenses | 429,567 | 441,759 | 523,839 |
| Loss from operations | (281,815) | (301,025) | (288,530) |
| Interest and other, net | |||
| Interest expense | (15,532) | (1,440) | (1,075) |
| Interest income and other income (expenses), net | 10,480 | 7,596 | (1,078) |
| Total interest and other, net | (5,052) | 6,156 | (2,153) |
| Loss before income taxes | (286,867) | (294,869) | (290,683) |
| Provision for income taxes | 3 | 358 | 347 |
| Investment income in unconsolidated variable interest entity | 2,638 | 1,573 | 1,007 |
| Net loss | $(284,232) | $(293,654) | $(290,023) |
| Net loss per share - basic and diluted | $(2.92) | $(3.14) | $(3.14) |
| Weighted average number of common shares used to calculate net loss per share - basic and diluted | 97,303 | 93,582 | 92,349 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.